2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination
Remyelination
2-Arachidonoylglycerol
Encephalomyelitis
DOI:
10.1523/jneurosci.2900-16.2017
Publication Date:
2017-07-28T01:00:39Z
AUTHORS (11)
ABSTRACT
The failure to undergo remyelination is a critical impediment recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, modulation of CSPGs deposition progressive model sclerosis, Theiler9s murine encephalomyelitis virus-induced disease. Treatment with potent reversible inhibitor enzyme monoacylglycerol lipase, which accounts 85% 2-AG degradation mouse CNS, modulates neuroinflammation reduces accumulation astrogliosis around demyelinated spinal cord virus-infected mice. Inhibition hydrolysis augments number mature oligodendrocytes increases MBP, leading functional Our findings establish mechanism promotion implications axonal repair pathologies. <b>SIGNIFICANCE STATEMENT</b> chondroitin contributes associated Here unveil 2-arachidonoylglycerol, proteoglycan treatment during chronic phase increased tone promotes sclerosis ameliorating motor dysfunction.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (53)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....